利拉鲁肽联合二甲双胍治疗肥胖新诊断2型糖尿病临床观察

•临床研穷•221年5月2日第3卷第10期Clinical Research China Pharmaceuticals Vol.50,No.(9,May20,202)

dh：i3969/j.imn.104-4931.202/10.01

利拉鲁肽联合二甲双胍治疗肥胖新诊断2型糖尿病临床观察*

赵晓南i王琴2

(/辽宁省沈阳市第五人民医院内分泌科，辽宁沈阳11026；2.沈阳医学院附属第三医院内分泌科，辽宁沈阳11026)

摘要：目的探讨利拉鲁肽联合二甲双胍治疗肥胖新诊断(<2年)2型糖尿病的疗效，以及对胰岛素抵抗和脂肪细胞因子的影响。方法选取沈阳市第五人民医院2017年6月至2019年6月收治的肥胖新诊断2型糖尿病患者148例，按随机数字表法分为观察组和对照组，各74例。两组患者均予常规治疗，并口服盐酸二甲双胍片，观察组患者加用利拉鲁肽注射液皮下注射,均治疗1周。结果观察组患者治疗后的空腹血糖、餐后2h血糖、空腹胰岛素、胰岛素抵抗指数，损伤性脂肪细胞因子内脂素、趋化素、瘦素，肿瘤坏死因子-a、白细胞介素6、血清淀粉样蛋白A水平均显著低于对照组，胰岛B细胞功能指数，保护性脂肪细胞因子人网膜素-1饱食分子水平均显著高于对照组(P<0.05);两组不良反应发生率相当(P>0.05)。结论利拉鲁肽联合二甲双胍治疗肥胖新诊断2型糖尿病有一定疗效，可调节脂肪细胞因子，减轻胰岛素抵抗，血糖控制效果较好，炎性反应较轻。

关键词：利拉鲁肽;二甲双胍;2型糖尿病；肥胖;胰岛素抵抗；脂肪细胞因子

中图分类号：R969.4;R971+.5文献标志码：A文章编号:1006-4931(2021)10-0072-03 Clinicei Observation of LPalutidc Combines with Metformin in the Treatmedt of Obese 9806x10with Newly Diaynosed Type2Diabetes”6X01

ZHAO Xiaonan1,WANG QUd

牗1,DegaOmeoi p Endocriaolopy,SOeuycng Figh PeopU s HospOd,SOeuycng,Liaoxing,Chian112426; 2.Degartmeot af'EndQcrioQlQpy,Thu Third Afilidfin HospUal O SSeuyaad MeUoal College,SO ucu，Liaoning,Chiun110426)

Abstract:Objective To investigate the eUicacy of Plalutibe comSineh with metfounin in the treatment of oPeso patients with newly(less than two years(diaanoseh type2diabetes meUitus(T2DM)anf Us eUect on insuhn resistance anf ahipocytoPines.Methods A total of 13oPeso patients with T2DM abmitted Pt the SSexyany Fifth People:s Hospiml from Juue201Pt June2019were selected anf rankom/Uivibed into the ohservation group and the control group,O4cases in each group.The paPexts in the two groups were given routine treatment anf Metformin Hydrechlo/be Tablets；on this Sasis；the patients in the oUseuahou group were given suPcntaneous in-jecUon of Liralutibe InjecPon.Both groups were treated for six weeds.Results After treatment,the levels of fastiny Sloop glucose (FBG),2-hour postprandial Sloop glucose(6hPG)anf fastiny serum insuhn(FINS),the Homeostasis mohei assessment P insu/n resis-mnce(HOMA-IR),the levels of visfatin,cheme/n anf leptin in traumatic aUipocytohines,tumor necrosis factor-a(TNF-a：, imerlenkin-4(IN-4)anf serum amyloib protein A(SAA)in the ohservation group were lower than those in the control group(P<0.05). The HOMA-B,the levels of protective aUipecytohines human omextin-1anf nesfatin-1in the ohservation group were sigmUcanUy higher than those in the control group(P<0.05).The incibexco P abverso reactions was similar Setween the two groups(P>0.05). Conclusion LUarutibe comSineh with metformin in the treatment of oPeso patients with newly diaanoseh T2DM can reyulato aUipocy-mhines anf reduce insuhn resistance with goop Sloop glucose control effect anf mil/iiUUmmhorg react!on.

Ke y words:UlarutiPe;metformin;type2diabetes melhtus-oPeso;insuhn resistance;aUipocytoUines

基金项目：辽宁省自然科学基金D0*******]。

第一作者:赵晓南，女，大学本科，主治医师，研究方向为内分泌疾病的诊疗，(电子信箱)zhhxnH33@。

参考文献

[1单敏，郑方晔，李锋武.RP-HPLC法测定复方倍他米松注射液有关物质[J..药物分析杂志,2008,28(4):624-626.

⑵孙艳,姜娟娟，李乔.复方倍他米松注射液肌内注射致过敏

性休克一例[J..实用皮肤病学杂志,201,1(4):253-254. [J.朱鑫鑫，沈金明.玻璃酸钠联合复方倍他米松注射液治疗膝关节骨性关节炎的临床疗效观察[J].中国现代医生,2013, 56(6):60-93.

[J.沈丹丹，肖波,姜学美，等.高效液相色谱法同时测定复方倍他米松注射液两主成分含量[J].中国药业,201,26(21):25-29.J〕沈丹丹，吴群，张涛.复方倍他米松注射混悬液溶出度方法的开发和验证[J..中国新药杂志,201,26(1):1512-1515. [2]JX20070074,复方倍他米松注射液进口注册标准[J..

[7]YBH01252015,复方倍他米松注射液标准[J..

⑻国家药典委员会.中华人民共和国药典(四部：皿〕.北京：

中国医药科技出版社，2020:15-17.

[J.The United States Pharmacopoeia-ConvexUon.The United States Pharmacopoeia42th EdiPon<4290Light Diffraction Measure­meht P PaUicte Size[M..Rochville MD:the United States Phar-macopoeial ConvehUon,2213:6624.

(收稿日期：2020-1-31)

72